Real World Data

Real-world evidence from year one of iLet commercial availability demonstrates:

  • Reduction in Average Glucose Level – Users experienced a significant and sustainable reduction from baseline HbA1c to follow-up GMI.
  • Increase in TIR – Users experienced a significant and sustainable increase in TIR from baseline therapy*.
  • Low Time in Hypo – The reduction in average glucose and increased time in range were achieved while maintaining a median time <54 mg/dL of 0.28% – about 1/4th the ADA goal of ≤1%.
  • Less Effort. Better Results – The iLet Bionic Pancreas System required much less effort from patients, with improved results consistent across high and low levels of patient engagement.
  • Reduced Burden for Providers – The iLet Bionic Pancreas System positively impacted all patient types, while reducing burden and time spent managing patients.
* Subset  of users with baseline data.
MM000205_A

Ready to GO BIONIC?

The iLet Bionic Pancreas automatically adjusts to your insulin needs so you don’t have to.